Related Experiment Video
Updated: Aug 13, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Convergent pathobiologic model of Parkinson's disease
Kathleen A Maguire-Zeiss1, Howard J Federoff
1Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA.
Annals of the New York Academy of Sciences
|July 9, 2003
Summary
Parkinson's disease (PD) may share a common pathway despite varied triggers. Research reviews synuclein models to find shared therapeutic targets for this neurodegenerative disorder.
Area of Science:
- Neuroscience
- Neurology
- Pathobiology
Background:
- The precise causes of Parkinson's disease (PD) remain unclear.
- Genetic studies and animal models indicate multiple initiating factors for this age-related neurodegenerative disorder.
- A common pathway model is proposed, suggesting shared pathophysiological mechanisms underlie both familial and sporadic PD.
Purpose of the Study:
- To review evidence supporting a common pathway model for Parkinson's disease.
- To explore synuclein transgenic models in the context of this common pathway.
- To identify shared therapeutic targets for Parkinson's disease and discuss alternative therapies.
Main Methods:
- Review of existing literature on Parkinson's disease etiology.
- Analysis of synuclein transgenic animal models.
- Discussion of potential therapeutic strategies.
Main Results:
- Evidence suggests that diverse triggers for Parkinson's disease may converge on a common pathobiologic pathway leading to neuronal cell death.
- Synuclein transgenic models provide support for this convergent pathway hypothesis.
- The common pathway model offers a framework for identifying shared therapeutic targets.
Conclusions:
- A common pathway model is a viable framework for understanding Parkinson's disease pathogenesis.
- Identifying shared targets could lead to more effective treatments for both familial and sporadic Parkinson's disease.
- Further research into synuclein models and alternative therapies is warranted.
Related Concept Videos
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...